LEADER 01216nam0-2200409---450 001 990005656960203316 005 20190517145007.0 035 $a000565696 035 $aUSA01000565696 035 $a(ALEPH)000565696USA01 035 $a000565696 100 $a20041104d1980----|||y0itaa50------ba 101 $aita 102 $ait 105 $a0 00||| 200 1 $aBarthes$fdi Roland Barthes$gtraduzione di Gianni Celati 210 $aTorino$cEinaudi$d1980 215 $a221 p.$cill.$d20 cm 225 2 $a<> struzzi$v220 300 $aTit. orig.: Roland Barthes par Roland Barthes. 410 0$12001$a<> struzzi$v220 454 $1001SA0011990$12001$aRoland Barthes par Roland Barthes.$924096 620 $dTORINO 676 $a848.9 700 1$aBARTHES,$bRoland$036036 702 1$aCELATI,$bGianni 801 0$aIT$bSA$c20111219 912 $a990005656960203316 950 0$aDipar.to di Filosofia - Salerno$dDFFDC BAR$e6346 FIL 951 $aXV.18.A. 92 (FDC BAR)$b6346 FIL 959 $aBK 969 $aFDECI 979 $c20121027$lUSA01$h1525 979 $c20121027$lUSA01$h1615 996 $aRoland Barthes par Roland Barthes$924096 997 $aUNISA NUM $aSA0011989 LEADER 05136nam 2200613Ia 450 001 9910437854103321 005 20200520144314.0 010 $a1-4614-6916-3 024 7 $a10.1007/978-1-4614-6916-2 035 $a(CKB)2670000000370315 035 $a(EBL)1697682 035 $a(OCoLC)904404043 035 $a(SSID)ssj0000894307 035 $a(PQKBManifestationID)11488102 035 $a(PQKBTitleCode)TC0000894307 035 $a(PQKBWorkID)10841738 035 $a(PQKB)11436945 035 $a(DE-He213)978-1-4614-6916-2 035 $a(MiAaPQ)EBC1697682 035 $a(PPN)17048811X 035 $a(EXLCZ)992670000000370315 100 $a20130522d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe challenge of CMC regulatory compliance for biopharmaceuticals and other biologics /$fJohn Geigert 205 $a2nd ed. 210 $aNew York $cSpringer$dc2013 215 $a1 online resource (362 p.) 300 $aDescription based upon print version of record. 311 $a1-4614-6915-5 320 $aIncludes bibliographical references and index. 327 $aComplexity of Biologica CMC Regulation -- Biologics are Not Chemical Drugs -- An Effective CMC Strategy is Possible -- Challenge of Adventitious Agent Control -- Source Materials for Biologics -- Manufacture of the Biologic API -- The Biologic Final Product Process -- Complex Process-Related Impurities -- Molecular Structural Analysis -- Functional Activity (Potency) -- Setting Specifications and Expiry Dates -- Demonstrating Product Comparability -- CMC-Focused Regulatory Meetings -- References. 330 $aAn effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery.  Through means of this 2nd edition, this no longer needs to occur.  A great deal of thanks goes to two regulatory authorities ? the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years.  So much has changed since the 1st edition of this book was published in 2004.  There are now additional manufacturing processes for producing commercial biopharmaceuticals ? transgenic plant cell cultures and transgenic animals.  In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy).  Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA.  Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu).  Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS).  The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition.  All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals).      About The Author   John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry.  Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry.  Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an expert member of the USP Biotechnology Committee.  Dr. Geigert has written extensively for the Regulatory Affairs Professional Society (RAPS) Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series) and Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series)). 606 $aPharmaceutical biotechnology 606 $aPharmaceutical biotechnology industry$xLaw and legislation 606 $aPharmaceutical biotechnology$xQuality control 615 0$aPharmaceutical biotechnology. 615 0$aPharmaceutical biotechnology industry$xLaw and legislation. 615 0$aPharmaceutical biotechnology$xQuality control. 676 $a610 676 $a615.15 676 $a615.19 676 $a615.3 700 $aGeigert$b J$g(John),$f1948-$091349 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437854103321 996 $aThe challenge of CMC regulatory compliance for biopharmaceuticals and other biologics$94195755 997 $aUNINA